CVXGA
COVID-19
Phase 2Active
Key Facts
About CyanVac
CyanVac is a clinical-stage biotech advancing a pipeline of intranasal vaccines based on its proprietary PIV5 viral vector platform. Its lead programs target COVID-19 and RSV, both in clinical trials, with preclinical work in pandemic flu, norovirus, and Lyme disease. The company's strategy focuses on generating robust mucosal immunity to potentially block infection and transmission, addressing key limitations of injectable vaccines. CyanVac operates as a private entity and appears to be pre-revenue, leveraging its platform for both proprietary programs and through its affiliate, Blue Lake Biotechnology.
View full company profileTherapeutic Areas
Other COVID-19 Drugs
| Drug | Company | Phase |
|---|---|---|
| COVID-19 Severity Prediction Test | Age Labs | Development |
| PanCytoVir™ (oral probenecid) | TrippBio | Phase 2 |
| ARCoV | Abogen | Approved (EUA) |
| OT-101 | Sapu BioScience | Clinical Trial (Phase not specified) |
| COVID-19 Vaccine (Inactivated) | Kangtai Biological Products | Approved |
| COVID-19 Vaccine (Adenovirus Vector) | Kangtai Biological Products | Approved |
| Idylla SARS-CoV-2 Test | Biocartis | Approved |
| Adjuvanted Cell-Based COVID-19 Vaccine | CSL Seqirus | Marketed |
| Sequential Dialysis Technique | Halberd | Discovery |
| Amubarvimab + Romlusevimab (BRII-196/BRII-198) | Brii Biosciences | Approved |
| COVID-19 Vaccine Testing (for AstraZeneca) | Advaxia Biologics | Approved |
| COVID-19 Vaccine Clinical Batches | Advaxia Biologics | Clinical |